Volume 41 Supplement 2

71st Congress of the Italian Society of Pediatrics

Open Access

Mycoplasma pneumoniae infection with neurologic complications

Italian Journal of Pediatrics201541(Suppl 2):A67

https://doi.org/10.1186/1824-7288-41-S2-A67

Published: 30 September 2015

Mycoplasma pneumoniae (M. pneumonia) is one of the important causes of upper and/or lower respiratory tract infections during childhood. Central nervous system (CNS) related findings and complications are most commonly seen and have been described in patients with M. pneumoniae infections [1, 2]. Patients suffering M. pneumoniae infection may have varying degrees of neurological complications at a ratio of approximately 6-7% [1, 2]. Neurological manifestations include encephalitis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), Guillain-Barre syndrome, and thromboembolic stroke [2]. The time period between the onset of respiratory symptoms and neurological symptoms varies 2 to 14 days [3, 4]. More than 80% of patients with CNS findings have concomitant respiratory infection [5].

Central nervous system complications have been reported with Mycoplasma infection. Cerebellar syndrome, polyradiculitis, cranial nerve palsies, aseptic meningitis, meningoencephalitis, acute disseminated encephalomyelitis, coma, optic neuritis, diplopia, mental confusion and, acute psychosis secondary to encephalitis, cranial nerve palsy, brachial plexus neuropathy, ataxia, choreoathetosis, and ascending paralysis (Guillain-Barre syndrome) are neurologic complications seen with M. pneumoniae infection [1].

Neuroimaging may reveal normal findings or focal diffuse edema in cases of encephalitis or meningoencephalitis. Patchy asymmetric or diffuse signal change of gray and white matter may be seen in patients with ADEM with multifocal, asymmetric foci of high signal intensity on FLAIR and T2 weighted images. A focal infarction may be seen with M. pneumoniae related stroke [4].

Treatment of neurologic complications of M. pneumoniae is controversial. Treatment may be adjusted according to infection mechanism such as antibiotics, corticosteroids, intravenous immunoglobulin [35]. Antimicrobial treatment, especially macrolides, may be sufficient for CNS involvement associated with M. pneumoniae, beside the beneficial effect of treatment with steroids this treatment must be considered with direct invasion of CNS by the organism when other causative agents have been excluded. Plasma exchange has also been reported and seemed to be beneficial.

Authors’ Affiliations

(1)
UOC Neurologia Pediatrica, Sapienza Università Roma

References

  1. Waites KB, Talkington DF: Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004, 17 (4): 697-728. 10.1128/CMR.17.4.697-728.2004.PubMedPubMed CentralView ArticleGoogle Scholar
  2. Christie LJ, Honarmand S, Talkington DF, Gavali SS, Preas C, Pan CY, et al: Pediatric encephalitis: what is the role of Mycoplasma pneumoniae?. Pediatrics. 2007, 120 (2): 305-313. 10.1542/peds.2007-0240.PubMedView ArticleGoogle Scholar
  3. Guleria R, Nisar N, Chawla TC, Biswas NR: Mycoplasma pneumonia and central nervous system complications: a review. J Lab Clin Med. 2005, 146 (2): 55-63. 10.1016/j.lab.2005.04.006.PubMedView ArticleGoogle Scholar
  4. Tsiodras S, Kelesidis I, Kelisidis T, Stamboulis E, Giamarellou H: Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect. 2005, 51 (5): 343-354. 10.1016/j.jinf.2005.07.005.PubMedView ArticleGoogle Scholar
  5. Shah SS: Mycoplasma pneumonia. Principles and Practice of Pediatric Infectious Diseases. Edited by: Long SS, Pickering LK, Prober CG. 2008, Churchill, Livingstone, 979-984. 3View ArticleGoogle Scholar
  6. Shibuya H, Osamura K, Hara K, Hisada T: Clinically mild encephalitis/encephalopathy with a reversible splenial lesion due to Mycoplasma pneumoniae infection. Intern Med. 2012, 51 (12): 1647-1648. 10.2169/internalmedicine.51.7676.PubMedView ArticleGoogle Scholar

Copyright

© Spalice. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement